2024
Treating Migraine Patients With Cardiovascular Risks
Wang K, Sico J. Treating Migraine Patients With Cardiovascular Risks. Neurology 2024, 103: e210196. PMID: 39621947, DOI: 10.1212/wnl.0000000000210196.Peer-Reviewed Original ResearchNonaspirin nonsteroidal anti-inflammatory drugsCardiovascular safety profileSafety profileCardiovascular eventsCardiovascular riskIncreased riskIncreased risk of ischemic eventsRisk of ischemic eventsNonsteroidal anti-inflammatory drugsExclusion of patientsAdverse cardiovascular eventsMyocardial infractionRisk of acute cardiovascular eventsEffective acute treatmentTreat migraine patientsRisk of myocardial infractionCOX-2 inhibitorsAnti-inflammatory drugsAcute cardiovascular eventsMigraine patientsAcute treatmentIschemic eventsManaging cardiovascular riskRandomized trialsCOX-2
2021
Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience
Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart 2021, 8: e001849. PMID: 34952868, PMCID: PMC8710909, DOI: 10.1136/openhrt-2021-001849.Peer-Reviewed Original ResearchConceptsCardiovascular adverse eventsAdverse Event Reporting SystemCombination therapyAntimicrotubular agentsVinca alkaloidsAdverse eventsDrug Administration Adverse Event Reporting SystemRoutine cardiovascular assessmentCardiovascular safety profilePolytomous logistic regressionEvent Reporting SystemAgent therapyCombination chemotherapyHeart failureRegistry experienceSafety profileCardiovascular assessmentHigh burdenInhibitor combinationsChemotherapeutic agentsTaxanesTherapyLogistic regressionMonotherapyReporting system
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply